Lonza Group (OTCMKTS:LZAGY – Get Free Report) was upgraded by research analysts at Redburn Atlantic to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.
Separately, The Goldman Sachs Group upgraded Lonza Group to a “strong-buy” rating in a research report on Wednesday, October 9th.
Check Out Our Latest Stock Analysis on Lonza Group
Lonza Group Price Performance
Lonza Group Company Profile
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Featured Articles
- Five stocks we like better than Lonza Group
- How to Evaluate a Stock Before Buying
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 11/25 – 11/29
- What is Forex and How Does it Work?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.